Treatment of Wilson disease with ammonium tetrathiomolybdate - IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease

Archives of Neurology

Volumn 63, Issue 4, 2006, Pages 521-527

  Brewer, George J ^a   Askari, Fred ^b   Lorincz, Matthew T ^b   Carlson, Martha ^b   Schilsky, Michael ^b   Kluin, Karen J ^b   Hedera, Peter ^b   Moretti, Paolo ^b   Fink, John K ^b   Tankanow, Roberta ^b   Dick, Robert B ^b   Sitterly, Julia ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COPPER; TETRATHIOMOLYBDATE AMMONIUM; TRIENTINE; ZINC;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; LEUKEMIA; LEUKOPENIA; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPEECH ANALYSIS; TIME SERIES ANALYSIS; TREATMENT DURATION; UNIVERSITY HOSPITAL; WILSON DISEASE;

ADOLESCENT; ADULT; ANEMIA; CHELATING AGENTS; COPPER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATOLENTICULAR DEGENERATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MOLYBDENUM; SERUM ALBUMIN; SPEECH; SPEECH DISORDERS; TREATMENT OUTCOME; TRIETHYLENETETRAMINE; ZINC;

EID: 33645733769     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.63.4.521     Document Type: Article

References (19)

1. Scheinberg IH, Sternlieb I. Wilson's disease. In: Smith LH Jr, ed. Major Problems in Internal Medicine. Vol 23. Philadelphia, Pa: WB Saunders Co; 1984.
2. Schilsky ML. Wilson disease: genetic basis of copper toxicity and natural history. Semin Liver Dis. 1996;16:83-95.
3. Brewer GJ, Askari FK. Wilson's disease: clinical management and therapy. J Hepatol. 2005;42(suppl):S13-S21.
4. Brewer GJ. Wilson's Disease: A Clinician's Guide to Recognition, Diagnosis, and Management. Boston, Mass: Kluwer Academic Publishers; 2001.
5. Brewer GJ. Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment. CNS Drugs. 2005;19:185-192.
6. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993;5:327-337.
7. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet. 1993;5:344-350.
8. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun. 1993;197:271-277.
9. Walshe JM. Penicillamine, a new oral therapy for Wilson's disease. Am J Med. 1956;21:487-495.
10. Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine. 1992;71:139-164.
11. Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet. 1982;1:643-647.
12. Yuzbasiyan-Gurkan V, Grider A, Nostrant T, Cousins RJ, Brewer GJ. Treatment of Wilson's disease with zinc, X: intestinal metallothionein induction. J Lab Clin Med. 1992;120:380-386.
13. Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK. Treatment of Wilson's disease with zinc, XV: long-term follow-up studies. J Lab Clin Med. 1998;132:264-278.
14. Hoogenraad TU, Van Hattum J, Van den Hamer CJA. Management of Wilson's disease with zinc sulfate: experience in a series of 27 patients. J Neurol Sci. 1987;77:137-146.
15. Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol. 1987;44:490-493.
16. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Tankanow R, Young AB, Kluin KJ. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol. 1991;48:42-47.
17. Brewer GJ, Dick RD, Johnson V, et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate, I: initial therapy in 17 neurologically affected patients. Arch Neurol. 1994;51:545-554.
18. Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA. Treatment of Wilson disease with ammonium tetrathiomolybdate, II: initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 1996;53:1017-1025.
19. Brewer GJ, Hedera P, Kluin KJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate, III: initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 2003;60:379-385.